Ontology highlight
ABSTRACT:
SUBMITTER: Sharma GG
PROVIDER: S-EPMC5876637 | biostudies-literature | 2018 Feb
REPOSITORIES: biostudies-literature
Sharma Geeta Geeta GG Mota Ines I Mologni Luca L Patrucco Enrico E Gambacorti-Passerini Carlo C Chiarle Roberto R
Cancers 20180228 3
Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-rearranged malignancies, particularly in non-small-cell lung cancer (NSCLC), which has generated considerable interest and effort in developing ALK tyrosine kinase inhibitors (TKI). Crizotinib was the first ALK inhibitor to receive FDA approval for ALK-positive NSCLC patients treatment. However, the clinical benefit observed in targeting ALK in NSCLC is almost universally limited by the emergence of drug resistance w ...[more]